Peripheral and central nervous system distribution of the CGRP neutralizing antibody [¹²⁵I] galcanezumab in male rats

Abstract

The central levels of galcanezumab were relatively low, which would favor the dura mater and trigeminal ganglia as sites of action for its observed clinical efficacy. However, a central site of action cannot be excluded.